CanAg Diagnostics Overview
- Year Founded
-
1992
- Status
-
Acquired/Merged
- Employees
-
79
- Latest Deal Type
-
M&A
CanAg Diagnostics General Information
Description
Developer of immunological reagents. The company develops monoclonal antibodies for the treatment of cancer, brain damage and tumors.
Contact Information
Website
www.canag.seCorporate Office
- Elof Lindälvs gata 13
- 414 55 Gothenburg
- Sweden
Corporate Office
- Elof Lindälvs gata 13
- 414 55 Gothenburg
- Sweden
CanAg Diagnostics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 31-May-2006 | Completed | Generating Revenue | |||
| 2. Angel (individual) | 01-Jan-2001 | Completed | Generating Revenue | |||
| 1. Early Stage VC | Completed | Startup |
CanAg Diagnostics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CanAg Diagnostics Patents
CanAg Diagnostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20070037180-A1 | Site-specific immunization in order to establish antibodies with specificity for the e7 oncoprotein of high-risk hpv's | Inactive | 10-Feb-2005 | ||
| ES-2376167-T3 | Immuno tests for the specific determination of scca isoforms. | Inactive | 10-Sep-2002 | ||
| CA-2498524-A1 | Immunoassays for specific determination of scca isoforms | Active | 10-Sep-2002 | ||
| US-20080057520-A1 | Monoclonal antibody for detecting squamous cell carcinoma antigen (scca); diagnostic indicator for cancer screening; immunodiagnostics | Inactive | 10-Sep-2002 | ||
| US-20040176577-A1 | Monoclonal antibody for classifiying squamous cell carcinoma antigen (scca) species and diagnosis of cell proliferative disorders | Inactive | 10-Sep-2002 | C07K16/30 |
CanAg Diagnostics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CanAg Diagnostics Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Industrifonden | Venture Capital | Minority | ||
| Líftæknisjóðurinn MP BIO hf | Venture Capital | Minority |
CanAg Diagnostics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Majira Real Estate 7 | Molndal, Sweden | 2017 |
CanAg Diagnostics FAQs
-
When was CanAg Diagnostics founded?
CanAg Diagnostics was founded in 1992.
-
Where is CanAg Diagnostics headquartered?
CanAg Diagnostics is headquartered in Gothenburg, Sweden.
-
What is the size of CanAg Diagnostics?
CanAg Diagnostics has 79 total employees.
-
What industry is CanAg Diagnostics in?
CanAg Diagnostics’s primary industry is Drug Discovery.
-
Is CanAg Diagnostics a private or public company?
CanAg Diagnostics is a Private company.
-
What is CanAg Diagnostics’s current revenue?
The current revenue for CanAg Diagnostics is .
-
Who are CanAg Diagnostics’s investors?
Industrifonden and Líftæknisjóðurinn MP BIO hf have invested in CanAg Diagnostics.
-
When was CanAg Diagnostics acquired?
CanAg Diagnostics was acquired on 31-May-2006.
-
Who acquired CanAg Diagnostics?
CanAg Diagnostics was acquired by Fujirebio Diagnostics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
